IMPAX to Present at UBS Warburg Global Specialty Pharmaceuticals Conference

May 31, 2002

Company Presentation Thursday, June 6, at 11:00 a.m. EDT

May 31, 2002 -- IMPAX Laboratories, Inc. (Nasdaq NM: IPXL) today announced that management will present at the UBS Warburg Global Specialty Pharmaceuticals Conference on Thursday, June 6, 2002, at 11:00 a.m. EDT.

The conference will be held at The Grand Hyatt New York in New York City and attendees will include institutional money managers and analysts.

IMPAX's presentation will be webcast and accessible to the investors on-line at Replays will be available the following business day for 30 days after the presentation at the same web site address or by visiting the investor relations section of IMPAX's Website at and following the link to the Company's presentation.

IMPAX currently has 15 ANDA filings pending at the FDA that address more than $8 billion in U.S. branded product sales. Nine of these filings were made under Paragraph IV of the Hatch-Waxman Amendments and three of these now have tentative approval from the FDA.

IMPAX Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and niche generics in addition to the development of branded products. IMPAX markets its generic products through its Global Pharmaceuticals division and intends to market its branded products through the IMPAX Pharmaceuticals division. IMPAX Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward and Philadelphia facilities. For more information, please visit the Company's Web site at: